Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients
Heavy drinking contributes to involuntary body movements such as akathisia. Quetiapine has been shown to alleviate symptoms of akathisia; however, its efficacy in the alcohol dependent population is not well established. Thus, we aimed to identify efficacy of Quetiapine in treating akathisia in very...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | Journal of Addiction |
Online Access: | http://dx.doi.org/10.1155/2016/6028971 |
id |
doaj-82df4f7f4d244d0d9262ba8e52fe313e |
---|---|
record_format |
Article |
spelling |
doaj-82df4f7f4d244d0d9262ba8e52fe313e2020-11-24T23:18:13ZengHindawi LimitedJournal of Addiction2090-78342090-78502016-01-01201610.1155/2016/60289716028971Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent PatientsZimple Kurlawala0Vatsalya Vatsalya1University of Louisville School of Medicine, University of Louisville, Louisville, KY, USAUniversity of Louisville School of Medicine, University of Louisville, Louisville, KY, USAHeavy drinking contributes to involuntary body movements such as akathisia. Quetiapine has been shown to alleviate symptoms of akathisia; however, its efficacy in the alcohol dependent population is not well established. Thus, we aimed to identify efficacy of Quetiapine in treating akathisia in very heavy drinking alcohol dependent patients. 108 male and female heavy alcohol consuming study participants received 13 weeks of Quetiapine XR. Drinking history (Timeline Followback, TLFB), depression (Montgomery-Asberg Depression Rating Scale, MADRS), and movement (Barnes Akathisia Scale, BARS) measures were collected at baseline (0 W), week 6 (6 W), and week 12 (12 W). The role of drinking, symptoms of depression, and efficacy of Quetiapine for treating akathisia were assessed. In patients with no symptoms of depression (low MADRS), Quetiapine treatment decreased symptoms of akathisia. Patients with clinically significant depression (high MADRS) reported a significant increase in akathisia measures at 6 W which eventually decreased at 12 W to below baseline levels. The increase in akathisia at 6 W corresponded with a significant increase in the patients’ total drinks and heavy drinking pattern. Treatment with Quetiapine progressively lowered the occurrence of akathisia in alcohol dependent patients who do not show symptoms of depression. Quetiapine treatment lowered akathisia over time in heavy drinkers who had clinically significant symptoms of depression.http://dx.doi.org/10.1155/2016/6028971 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zimple Kurlawala Vatsalya Vatsalya |
spellingShingle |
Zimple Kurlawala Vatsalya Vatsalya Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients Journal of Addiction |
author_facet |
Zimple Kurlawala Vatsalya Vatsalya |
author_sort |
Zimple Kurlawala |
title |
Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients |
title_short |
Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients |
title_full |
Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients |
title_fullStr |
Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients |
title_full_unstemmed |
Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients |
title_sort |
heavy alcohol drinking associated akathisia and management with quetiapine xr in alcohol dependent patients |
publisher |
Hindawi Limited |
series |
Journal of Addiction |
issn |
2090-7834 2090-7850 |
publishDate |
2016-01-01 |
description |
Heavy drinking contributes to involuntary body movements such as akathisia. Quetiapine has been shown to alleviate symptoms of akathisia; however, its efficacy in the alcohol dependent population is not well established. Thus, we aimed to identify efficacy of Quetiapine in treating akathisia in very heavy drinking alcohol dependent patients. 108 male and female heavy alcohol consuming study participants received 13 weeks of Quetiapine XR. Drinking history (Timeline Followback, TLFB), depression (Montgomery-Asberg Depression Rating Scale, MADRS), and movement (Barnes Akathisia Scale, BARS) measures were collected at baseline (0 W), week 6 (6 W), and week 12 (12 W). The role of drinking, symptoms of depression, and efficacy of Quetiapine for treating akathisia were assessed. In patients with no symptoms of depression (low MADRS), Quetiapine treatment decreased symptoms of akathisia. Patients with clinically significant depression (high MADRS) reported a significant increase in akathisia measures at 6 W which eventually decreased at 12 W to below baseline levels. The increase in akathisia at 6 W corresponded with a significant increase in the patients’ total drinks and heavy drinking pattern. Treatment with Quetiapine progressively lowered the occurrence of akathisia in alcohol dependent patients who do not show symptoms of depression. Quetiapine treatment lowered akathisia over time in heavy drinkers who had clinically significant symptoms of depression. |
url |
http://dx.doi.org/10.1155/2016/6028971 |
work_keys_str_mv |
AT zimplekurlawala heavyalcoholdrinkingassociatedakathisiaandmanagementwithquetiapinexrinalcoholdependentpatients AT vatsalyavatsalya heavyalcoholdrinkingassociatedakathisiaandmanagementwithquetiapinexrinalcoholdependentpatients |
_version_ |
1725581465722290176 |